(Q37281824)

English

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

scientific article published on 07 July 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 (English)

1 reference

Europe PubMed Central

19 August 2017

24

object named as

Paul Workman

1 reference

Europe PubMed Central

19 August 2017

author name string

Florence I Raynaud

1

1 reference

Europe PubMed Central

19 August 2017

Suzanne A Eccles

2

1 reference

Europe PubMed Central

19 August 2017

Sonal Patel

3

1 reference

Europe PubMed Central

19 August 2017

Sonia Alix

4

1 reference

Europe PubMed Central

19 August 2017

Gary Box

5

1 reference

Europe PubMed Central

19 August 2017

Irina Chuckowree

6

1 reference

Europe PubMed Central

19 August 2017

Adrian Folkes

7

1 reference

Europe PubMed Central

19 August 2017

Sharon Gowan

8

1 reference

Europe PubMed Central

19 August 2017

Alexis De Haven Brandon

9

1 reference

Europe PubMed Central

19 August 2017

Francesca Di Stefano

10

1 reference

Europe PubMed Central

19 August 2017

Angela Hayes

11

1 reference

Europe PubMed Central

19 August 2017

Alan T Henley

12

1 reference

Europe PubMed Central

19 August 2017

Letitia Lensun

13

1 reference

Europe PubMed Central

19 August 2017

Giles Pergl-Wilson

14

1 reference

Europe PubMed Central

19 August 2017

Anthony Robson

15

1 reference

Europe PubMed Central

19 August 2017

Nahid Saghir

16

1 reference

Europe PubMed Central

19 August 2017

Alexander Zhyvoloup

17

1 reference

Europe PubMed Central

19 August 2017

Edward McDonald

18

1 reference

Europe PubMed Central

19 August 2017

Peter Sheldrake

19

1 reference

Europe PubMed Central

19 August 2017

Stephen Shuttleworth

20

1 reference

Europe PubMed Central

19 August 2017

Melanie Valenti

21

1 reference

Europe PubMed Central

19 August 2017

Nan Chi Wan

22

1 reference

Europe PubMed Central

19 August 2017

Paul A Clarke

23

1 reference

Europe PubMed Central

19 August 2017

publication date

7 July 2009

1 reference

Europe PubMed Central

19 August 2017

Molecular Cancer Therapeutics

1 reference

Europe PubMed Central

19 August 2017

8

1 reference

Europe PubMed Central

19 August 2017

1725-1738

1 reference

Europe PubMed Central

19 August 2017

7

1 reference

Europe PubMed Central

19 August 2017

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

PI3K pathway alterations in cancer: variations on a theme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Class I PI3K in oncogenic cellular transformation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

AKT signaling in regulating angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Pharmacodynamic biomarkers for molecular cancer therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Oncogenic PI3K deregulates transcription and translation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Phosphoinositide 3-kinase signalling--which way to target?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

The phosphoinositide 3-kinase pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Role of the PI3K regulatory subunit in the control of actin organization and cell migration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Signaling by distinct classes of phosphoinositide 3-kinases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

The role of phosphoinositide 3-kinase lipid products in cell function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Phosphoinositide 3-kinases: a conserved family of signal transducers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

14 September 2017

Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

14 September 2017

Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

14 September 2017

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

14 September 2017

Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

14 September 2017

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

14 September 2017

PI3K: downstream AKTion blocks apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

28 September 2017

Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

26 June 2018

Inhibiting PI-3-K for glioma therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

3 September 2018

The PI3K inhibitor arsenal: choose your weapon!

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

3 September 2018

Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

3 September 2018

PIK3CA is implicated as an oncogene in ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

3 September 2018

Structure and function of phosphoinositide 3-kinases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

3 September 2018

Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/19584227

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19584227

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1535-7163.MCT-08-1200

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37281824&oldid=1403700578"